Two RNA-binding proteins mediate the sorting of miR223 from

mitochondria into exosomes

Liang Ma[1], Jasleen Singh[1], and Randy Schekman[1] [*]

[1]Department of Molecular and Cell Biology, Howard Hughes Medical

Institute, University of California, Berkeley, United States.

[*]For correspondence: schekman@berkeley.edu

Abstract

Fusion of multivesicular bodies (MVBs) with the plasma membrane results in the secretion of intraluminal vesicles (ILVs), or exosomes. The sorting of one exosomal cargo RNA, miR223, is facilitated by the RNA-binding protein, YBX1 (Shurtleff et al., 2016). We found that miR223 specifically binds a "cold shock" domain (CSD) of YBX1 through a 5' proximal sorting motif UCAGU. Prior to sorting into exosomes, most of the cytoplasmic miR223 resides in mitochondria. An RNA-binding protein localized to the mitochondrial matrix, YBAP1, appears to serve as a negative regulator of miR223 enrichment into exosomes. miR223 levels decreased in the mitochondria and increased in exosomes after loss of YBAP1. We observed YBX1 shuttle between mitochondria and endosomes in live cells. YBX1 also partitions into P body granules in the cytoplasm (Liu et al., 2021). We propose a model in which miR223 and likely other miRNAs are stored in mitochondria and are then mobilized by YBX1 to cytoplasmic phase condensate granules for capture into invaginations in the endosome that give rise to exosomes.

Introduction

Extracellular vesicles (EVs) bud from the plasma membrane or are secreted when multivesicular bodies (MVB) fuse with the plasma membrane to release a population of vesicles called exosomes. EVs and their cargos are highly dependent on their membrane source. Microvesicles

released by budding from the plasma membrane are a heterogeneous population of EVs ranging in size from 30 nm to 1000 nm (Cocucci et al., 2009). Exosomes are 30 nm to 150 nm in size and originate as vesicles invaginated into the interior of an MVB to form intraluminal vesicles (ILVs) (Harding et al., 1983).

Many RNAs are selectively sorted into EVs, especially small RNAs. Several studies have indicated that RNA binding proteins (RNPs) may be involved in the enrichment of RNAs into EVs (Mukherjee et al., 2016; Santangelo et al., 2016; Teng et al., 2017; Villarroya-Beltri et al., 2013). However, many of these studies used sedimentation at ~100,000 g to collect EVs, which may also collect RNP particles not enclosed within membranes which complicates the interpretation of these data. To address this question, we previously developed buoyant density-based methods separate EVs from non-vesicular aggregates and found that EVs form two distinct populations of high and low buoyant density (Shurtleff *et al.*, 2016; Temoche-Diaz et al., 2020) . We found that some miRNAs are selectively enriched in a high buoyant density vesicle fraction characterized by an enrichment in the exosomal marker protein CD63, whereas the low buoyant density EVs are fairly non-selective in the capture of miRNAs (Temoche-Diaz et al., 2019). We developed a cell-free reaction to identify YBX1 as required for miR223 sorting into exosomes and demonstrated that it plays an important role in the enrichment of miR223 into exosomes in HEK293T cells (Shurtleff *et al.*, 2016). We subsequently found that phase separated YBX1 condensates selectively recruit miR223 in vitro and sort it into exosomes in cells (Liu *et al.*, 2021). In this study we report that YBX1 directly and specifically binds miR223 by its "cold shock" domain (CSD). We have identified a positive

sorting motif, UCAGU, in miR223 for sorting into exosomes. We also found a significant fraction of cytoplasmic miR223 localized within mitochondria, tightly associated with the mitochondrial envelope and that a mitochondrial RNA-binding protein, YBAP1, may control the transfer of miR223 from mitochondria to exosomes.

Results

YBX1 directly and specifically binds miR223

We previously documented that YBX1 facilitates miR223 sorting into exosomes (Shurtleff *et al.*, 2016) and that exosomal miR223 is decreased in YBX1 knockout cells (Liu *et al.*, 2021). We reexamined the enrichment and confirmed that exosomal miR223 was decreased in exosomes purified from YBX1 KO cells (Figure 1a).

Whereas the importance of YBX1 for miR223 sorting has been established, the mechanism of their interaction was not known. To examine the direct interaction of YBX1 and miR223, we used an electrophoretic mobility shift assay (EMSA) with purified recombinant YBX1, expressed in insect cells (Figure 1 supplement 1a), and chemically synthetic miR223 and miR190, a cytoplasmic miRNA that is not enriched in exosomes. Purified YBX1 was titrated and incubated with 5' fluorescently labeled miR223 at 30℃ for 30min. miR223-YBX1 complexes were separated by electrophoresis and detected by in-gel fluorescence. The EMSA data showed that YBX1 directly and specifically bound to miR223 but ~50-fold less well with miR190 (Figure 1b-c). The measured Kd for YBX1:miR223 was 5.3nM (Figure 1d).

YBX1 has three major domains including an N-terminal alanine/proline-rich

(A/P) domain, a central cold shock domain (CSD) and a C-terminal domain

(CTD) (Figure 1e). To explore which specific domain of YBX1 binds

miR223, we constructed a series of fragments: the A/P domain, CSD and

CTD (Figure 1f). The YBX1 fragments were expressed in and purified from

insect cells (Figure 1 supplement 1b). EMSA data showed that the A/P

domain and CTD had little or no affinity for miR223, whereas the CSD

domain retained some binding affinity but not as much as full length YBX1.

We then constructed two combined fragments of the A/P and CSD and

CSD and CTD domains (Figure 1 supplement 1c). The EMSA data

showed that the A/P domain was dispensable and the CSD plus CTD

bound miR223 comparable to full length of YBX1 (Figure 1f). Thus, CTD

may facilitate the folding of CSD to restore full binding to miR223.

YBX1-F85A in the CSD domain was reported to block the YBX1-specific

binding of mRNA (Lyons et al., 2016). Purified YBX1-F85A protein failed to

bind miR223 (Figure 1g, Figure 1 supplement 1c). These data suggest that

YBX1 directly and specifically binds miR223 via the CSD. The CTD of

YBX1 did not appear to directly bind miR223 but may facilitate a higher

affinity interaction with miR223.

117 Finding the miR223 binding motif for binding with YBX1 and

118 enrichment into exosomes

We next sought to determine the miR223 sequence motif responsible for

interaction with YBX1 and enrichment into exosomes. We used an EMSA

competition assay with a series of miR223 mutants. Purified YBX1 and 5'

fluorescently labeled miR223 were incubated with miR223 mutant

constructs titrated in a range from 1nM to 1μM. miR223 variants in a

binding domain should not compete for interaction of YBX1 with 5'

fluorescently tagged miR223 whereas variations in sequences irrelevant to

interaction would compete. Using this EMSA competition assay to screen

the miR223 binding motif, we found that the binding affinity of miR223mut

(3-6) and miR223mut (4-7) were decreased (Figure 2 supplement 1). This

suggested that the sequence UCAGU was critical for interaction with YBX1.

To test this directly, we employed a variant sequence, termed miR223mut,

where the UCAGU was substituted with AGACA. As a positive control, we

employed a variant of miR190, miR190sort, where the sequence AUAUG

was substituted with UCAGU (Figure 2a). EMSA data showed a reduced

YBX1 interaction of ~ 50-fold with miR223mut whereas the affinity of

miR190sort with YBX1 was increased ~10 fold compared with the

respective wt sequences.

To test whether this motif is critical for miR223 enrichment into exosomes,

we purified exosomes from 293T cells transiently transfected to

overexpress one of the four miRNA constructs (Figure 2d). RT-qPCR data

showed that the level of miR223 in exosomes was ~ 4-fold dependent on

the putative exosomal sorting motif (Figure 3e) and the enrichment of

miR190sort into exosomes was increased ~5-fold compared to miR190 WT

(Figure 2f).

In previous work, we developed a cell-free reaction to test the biochemical

requirement for YBX1 in the sorting of miR223 into vesicles formed with

membranes and cytosol isolated from broken HEK293 cells (Shurtleff et al.

2016). We have now refined this assay to measure the incorporation of ^{32}P-

5' end-labeled wt and mutant miR223 into vesicles formed *in vitro.*   After

incubation of permeabilized cells and isolated cytosol with ^{32}P-labled wt or

mutant miR223 at 30 °C for 20min, RNase I was added to digest any

unpackaged miRNA and in controls with 1% Triton X-100 to measure

background RNase resistant radiolabel. Samples were resolved on a gel

for visual and quantitative evaluation of membrane sequestered RNA

(Figure 2g and 2h). This data suggested that the UCAGU motif is critical for

miR223 packaging into vesicles in the cell-free reaction.

Taken together the results in Fig. 2 show that the miR223 sequence

UCAGA is a sorting signal for binding YBX1, for sorting this miRNA into

vesicles as a prelude to secretion and for the export of miR223 in

exosomes secreted from HEK293 cells.

Mitochondria contribute to miR223 enrichment into exosomes.

In a recent study we showed that YBX1 is sorted into P-bodies in cells and

that these biomolecular condensates may initiate the sorting of miR223 into

vesicles budding into the interior of endosomes (Liu *et al.*, 2021; Shurtleff *et*

al., 2016). Mitochondria represent another apparent intracellular location of

miR223 (Wang et al., 2020). We sought to evaluate the localization of

miR223 in cells using transfected fluorescently tagged RNA. Hela cells

expressing Tom22-mCherry as a mitochondrial marker were transiently

transfected with fluorescently labeled miR223 and evaluated by confocal

fluorescence microscopy and fluorescence intensity analysis. The

exogenous miR223 appeared coincident with the mitochondrial marker

protein (Figure 3a).

We then used cell fractionation of homogenates of HEK293 cells to

evaluate the subcellular distribution of endogenous miR223. Fractionation

was evaluated by immunoblot using marker proteins characteristic of

various cell organelles (Figure 3b). RNA extracted from isolated

membranes confirmed that miR223 but not miR190 was significantly

enriched in mitochondria but not in ER or cytosol (Figure 3c, Figure 3

supplement 1a) (Wang *et al.*, 2020).

To determine the organization of miR223 on or within mitochondria, we

prepared mitoplasts using digitonin to strip away the mitochondrial outer

membrane followed by fractionation on a Percoll density gradient.

Immunoblots of the enriched mitochondria and isolated mitoplasts showed

that the outer membrane, marked by Tom20, was largely removed with

retention of the inner membrane marker Tim23 (Figure 3d). RNA was

extracted from the purified mitoplast and RT-qPCR data indicated that

miR223 was enriched along with mRNA for COX1, but not with nuclear U6

snRNA (Figure 3e). We also used IP to purify mitochondria (Figure 3

supplement 1b) and either Triton X-100 to solubilize the membrane or

freeze-thaw to allow the matrix and envelope fractions to be separated by

centrifugation. Mitochondrial membrane proteins, such as Tom20 and COX

IV, were solubilized and retained in the supernatant fraction (Figure 3

supplement 1c). The freeze-thaw regimen released citrate synthase to a

supernatant fraction whereas Tom20 and COXIV sedimented in the pellet

fraction. RNA was extracted from the detergent supernatant and pellet

fractions where we found by RT-qPCR similar distributions of COX1 and

miR223 suggesting that COX1 mRNA and miR223 were not as readily

solubilized as the inner and outer membrane proteins (Figure 3 supplement

1d). RT-qPCR quantification of fractions from the freeze-thaw regimen

showed that both COX1 mRNA and miR223 remained largely associated

with the sedimentable membrane fraction (Figure 3 supplement 1e). We

conclude that miR223 is enclosed within mitochondria, possibly in

association with the inner membrane.

We sought a further test of the cellular location of miR223 within cells. For

this purpose, we generated cells depleted of mitochondria (Correia-Melo et

al., 2017). GFP-Parkin expressing U-2 OS cells were treated with CCCP for

48h, conditions that cause mitochondria to be removed by mitophagy. We

confirmed mitochondrial depletion after CCCP treatment by RT-qPCR of

mitochondrial COX1 mRNA (Figure 3f) and immunoblot of the

mitochondrial inner membrane marker Tim23 (Figure 3g). We then

compared the levels of both miR223 and miR190 from GFP-Parkin

expressing U-2 OS cells with and without CCCP treatment. RT-qPCR data

showed that miR223, but not miR190, increased 3-fold in cells treated with

CCCP (Figure 3h). To test the possibility that miR223 accumulated in cells

as a result of a failure of mobilization into exosomes, we compared the

miR223 levels in exosomes purified from untreated and CCCP treated cells

(Fig. 3i and j). We found that CCCP treatment lowered the amount of

miR223 in EVs 3-fold (Figure 3j). The 3-fold increase in cellular at the

expense of exosomal miR223 may reflect a critical role for mitochondria in

the mobilization of this RNA to exosomes.

YBAP1 binds miR223 in the mitochondria and in vitro.

In the course of purifying a tagged version of YBX1 from 293T cells, we

observed another protein that copurified and found that it corresponded to

YBAP1 (Figure 4a, b). Such a complex of YBX1 and YBAP1 has previously

been reported (Matsumoto et al., 2005). We confirmed that purified YBX1

and YBAP1 bind each other by coexpression and affinity purification from

insect cells (Figure 4 supplement 1b). YBAP1 is a mitochondrial matrix

protein with a standard N-terminal transit peptide sequence (Muta et al.,

1997). We confirmed this mitochondrial localization in U-2 OS cells

expressing Tom22-mCherry transiently transfected with a YBAP1-GFP

construct (Figure 4c-d). We also showed that YBAP1 is localized within

mitochondria by performing a proteinase K protection assay on purified

mitochondria. Mitochondria were isolated from non-transfected cells and

exposed to proteinase K in the presence or absence of Triton X-100 and

the degradation of YBAP1 was evaluated by immunoblot. YBAP1 was

resistant to proteinase K digestion as was the mitochondrial inner

membrane marker Tim23 and degraded upon membrane permeabilization

with Triton X-100 (Figure 4e), consistent with the localization of YBAP1

within mitochondria.

To test whether YBAP1 was bound to miR223 in mitochondria, we used

YBAP1 immunoprecipitation with mitochondria purified by fractionation on a

Percoll density gradient (Figure 4f). RT qPCR data showed that

mitochondrial miR223 was immunoprecipitated by YBAP1 antibody but not

by a control antibody (Figure 4g). To determine whether the YBAP1 and

miR223 interaction was direct, we used the EMSA assay and found that

purified YBAP1 bound miR223, but not miR190. The YBAP1 interaction

with miR223 was not dependent on the RNA sequence motif to which

YBX1 bound (Figure 4 supplement 2a-b). Taken together, these data

suggest that YBAP1 binds miR223 in the mitochondria and in vitro.

251 YBAP1 may control the transit of miR223 from mitochondria to

252 exosomes

To investigate the function of YBAP1 in the transit of miR223 into

exosomes, we generated a 293T YBAP1 KO cell line and compared the

level of miR223 enrichment in exosomes and mitochondria isolated from

WT and mutant cells (Figure 5a, b). RT-qPCR analysis showed that

miR223 decreased 2-fold in mitochondria but increased 2-fold in exosomes

purified from mutant and WT cells (Figure 5c, d). This apparent inverse

relationship is consistent with a role for YBAP1 protein in the retention of

miR223 in mitochondria.

262 YBX1 puncta shuttled from mitochondria to endosomes

In previous work we reported the localization of YBX1 to P-bodies and

suggested this may represent an intermediate stage in the concentrative

sorting of miRNAs for secretion in exosomes (Liu *et al.*, 2021). In other

earlier work, P-bodies were seen in association with mitochondria (Huang

et al., 2011). To explore this possibility, we visualized endogenous YBX1

and YBAP1 by IF and observed YBX1 puncta colocalized with the

mitochondria (Figure 6a). In order to detect the proximity of endosomes to

this point of contact between YBX1 puncta and mitochondria, we used U-2

OS cells transfected with Rab5(Q79L)-mCherry, which we employed

previously to enlarge and detect the internalization of YBX1 into

endosomes (Liu *et al.*, 2021). We then used three color visualization of the

U-2 OS cells also transfected with YFP-YBX1 and mito-BFP. Time-lapse imaging showed YBX1 puncta in close proximity to mitochondria or endosomes, followed quickly by transfer between them (Figure 6b). Taken together, these data suggest a mechanism whereby miR223 stored in mitochondria, possibly sequestered by YBAP1, may be captured in a tighter interaction with YBX1 in P-bodies and delivered to endosomes for sorting and secretion in exosomes.

Discussion

Selected miRNAs are sorted, some with very high fidelity, into invaginations in the endosome that give rise to exosomes secreted from cultured human cells and likely from many if not all cells in metazoan organisms. The means by which these miRNAs are sorted and the possible extracellular functions they serve is a subject of interest in normal and disease physiology. Here we report the role of the RNA-binding protein YBX1 and a sorting signal on one target RNA, miR223, and the indirect path miR223 may take from storage in mitochondria into exosomes.

We have identified a sorting signal on miR223, UCAGU, responsible for high affinity interaction with YBX and for sorting into vesicles formed in a cell-free reaction as well as for secretion in exosomes by HEK293 cells. The YBX1 protein has three distinct domains, one of which, the cold-shock domain (CSD) appears to be the principal site for RNA binding, including at least one critical residue, F85, required for binding miR223 as well as other RNAs (Lyons *et al.*, 2016). The C-terminal domain (CTD) includes an intrinsically disordered domain (IDR) that promotes the formation of a

liquid-liquid phase separation likely responsible for the organization of
YBX1 in P-bodies(Liu *et al.*, 2021). This domain does not itself interact with
RNA, but it appears to facilitate the folding or stabilization of the CSD to
promote high affinity binding to miR223.

In other work using a similar approach, we identified two separate sorting
signals, a 5'UGGA and a 3'UUU, on miR122 to which the RNA-binding
protein La binds *en route* to secretion in exosomes by the breast cancer
cell line MDA-MB-231(Temoche-Diaz *et al.*, 2019). Other distinct sorting
signals and their cognate RNA-binding proteins have been documented in
different cell lines. miRNAs with a GGAG sorting motif recognized by a
sumolyated form of hnRNPA2B1 was shown to be enriched in exosomes
(Villarroya-Beltri *et al.*, 2013). Another sequence, AAUGC, was found to be
enriched in exosomal miRNA and dependent on the RNA-binding protein
FMR1 for miRNA secretion (Wozniak et al., 2020). Diverse cell lines and
likely tissues appear to invoke distinct sorting signals decoded by different
RNA-binding proteins. Many of the proteins may engage in biomolecular
condensates such as P-bodies as a mechanism to sort RNAs for secretion
(Liu *et al.*, 2021).

miR223 appears to be an example of a number of small nuclear-encoded
RNAs localized to mitochondria (Jeandard et al., 2019). In some cases
these RNAs, such as tRNAs, serve an essential function such as in
mitochondrial protein synthesis, however, for miRNAs with no obvious
mitochondrial genome target, the function remains unclear (Jeandard *et al.*,
2019). Nonetheless, others have documented the localization of these
miRNAs enclosed within the mitochondrion and in the case of miR223, it
appears to be tightly associated with the inner membrane. The exact

organization and function of miR223 in this location remains to be

investigated but in the context of exosomal secretion, the mitochondrial

localization appears to serve as a reservoir.

In relation to the mitochondrial localization of miR223, we found a

mitochondrial RNA-binding protein, YBAP1, that copurified with a tagged

form of YBX1 expressed in HEK293 cells. YBAP1 has previously been

reported to interact with YBX1 and independently found associated with

mitochondria where its localization is dependent on an N-terminal transit

peptide sequence (Muta *et al.*, 1997). The association of mitochondrial

YBAP1 and cytoplasmic YBX1 was reproduced by coexpression of

recombinant forms of the two proteins in Baculovirus-infected SF9 cells

(Figure 4 supplement 1b). YBAP1 binds miR223 selectively but with an

affinity significantly below that of YBX1 (Figure 4h-j). Although YBX1 does

not localize to the mitochondrion, the stable interaction of the complex may

suggest a transient relationship, perhaps during the biogenesis of YBAP1

as it transits from the cytoplasm into the mitochondrion.

A functional relationship between YBAP1 and YBX1 is suggested by the

reduction in miR223 in mitochondria and increase in secretion of miR223 in

exosomes secreted from YBAP1 KO cells (Fig. 5). In contrast, removal of

mitochondria by treatment of cells with CCCP resulted in an increase in

cytoplasmic miR223 at the expense of secretion in exosomes (Fig. 3).

Although YBAP1 may facilitate the retention of miR223 within mitochondria,

mitochondrial RNA import and export may serve an independent role in the

selective capture of miRNAs by YBX1 in cytoplasmic P-body condensates.

YBX1 puncta appear to shuttle between mitochondria and endosomes at

which point miR223 bound to YBX1 may be further sorted into
invaginations budding into the interior of endosomes.

The highly selective nature of miRNA sorting and secretion in exosomes
suggests an important role in the trafficking of miRNAs between cells.
Numerous studies have suggested a role for secreted miRNAs in recipient
cells (Cha et al., 2015; Mittelbrunn et al., 2011; Pegtel et al., 2010; Valadi
et al., 2007). Nonetheless, as miRNAs ordinarily act stoichiometrically on
target mRNAs, the extremely low abundance and copy number of
miRNAs/vesicle is hard to reconcile with such a functional role of secreted
miRNA (Chevillet et al., 2014; Shurtleff et al., 2017) . Our observation that
the bulk of cellular miR223 is held within mitochondria suggests an
alternative role in some structural or regulatory process, perhaps essential
for mitochondrial homeostasis, controlled by the selective extraction of
unwanted miRNA into RNA granules and further by secretion in exosomes.

373 **Materials and methods**

374 Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Cell line (Spodoptera frugiperda)	Sf9	Other		Cell culture facility at UC Berkeley
Cell line (Homo sapiens)	HEK 293T cells	Other		Cell culture facility at UC Berkeley
Cell line (Homo sapiens)	HEK 293T-YBX1 KO cells	Other		Obtained by CRISPR-Cas9 in Schekman Lab
Cell line (Homo sapiens)	HEK 293T-YBAP1 KO	This study		Obtained by CRISPR-Cas9 in Schekman Lab
Cell line (Homo sapiens)	HEK 293T-3xHA-EGFP-OMP25	This study		Obtained by overexpression of pLJM1-3XHA-EGFP-OMP25 in Schekman lab
Cell line (Homo sapiens)	U-2OS cells			
Cell line (Homo sapiens)	U-2OS Parkin-GFP cells	This study		Obtained by overexpression of Parkin-GFP in Schekman lab
Recombinant DNA reagent	pFastBac His6 MBP N10 TEV LIC cloning vector (4C)	Addgene	RRID: Addgene_30116	N/A
Recombinant DNA reagent	Tom22-mCherry (plasmid)	This study		Gift of Dr Li Yu lab
Recombinant DNA reagent	His-MBP-YBX1 (plasmid)	This study		To express YBX1 in insect cells. Plasmid

				maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(1-51) (plasmid)	This study		To express YBX1(1-51) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(52-129) (plasmid)	This study		To express YBX1(52-129) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(130-324) (plasmid)	This study		To express YBX1(1-51) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(1-129) (plasmid)	This study		To express YBX1(1-129) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBX1(F85A) (plasmid)	This study		To express YBX1(F85A) in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	His-MBP-YBAP1 (plasmid)	This study		To express YBAP1 in insect cells. Plasmid maintained in Schekman lab
Recombinant DNA reagent	Mito-BFP			Gift of Dr. Samantha Lewis lab
Recombinant DNA reagent	mCherry-Rab5(Q79L) (plasmid)	Addgene	RRID: Addgene_35138	
Recombinant DNA reagent	pLJM1-3XHA-EGFP-OMP25	This study		To express 3xHA-EGFP-OMP25 in HEK293T cells. Plasmid maintained

				in Schekman lab
Antibody	Anti-YBX1 (Rabbit polyclonal)	Abcam	RRID: AB_1950384	WB 1:1000
Antibody	Anti-YBAP1 (Mouse monoclonal)	Santa Cruz	RRID: AB_10611471	WB 1:1000
Antibody	Anti-YBAP1(Rabbit polyclonal)	Thermo Fisher Scientific	RRID: AB_2638956	WB 1:1000
Antibody	Anti-Tim23 (Mouse monoclonal)	BD Biosciences	RRID: AB_398754	WB 1:1000
Antibody	Anti-Tom20 (Mouse monoclonal)	Abcam	RRID: AB_945896	WB 1:1000
Antibody	Anti-Calnexin (Rabbit polyclonal)	Abcam	RRID: AB_2069006	WB 1:2000
Antibody	Anti-HA (Rabbit monoclonal)	Cell Signaling	RRID: AB_1549585	WB 1:1000
Antibody	Anti-COX IV (Rabbit Monoclonal)	Cell signaling	RRID: AB_2085424	WB 1:1000
Antibody	Anti-Citrate Synthase (Rabbit monoclonal)	Cell signaling	RRID: AB_2665545	WB 1:1000
Antibody	Anti-Rab5 (Rabbit monoclonal)	Cell signaling	RRID: AB_2300649	WB 1:1000
Antibody	Anti-LAMP1 (Rabbit monoclonal)	Cell signaling	RRID: AB_2687579	WB 1:1000
Antibody	Anti-GRP78 (Rabbit polyclonal)	Abcam	RRID: AB_2119834	WB 1:3000
Antibody	Anti-GADPH (Rabbit monoclonal)	Cell signaling	RRID: AB_561053	WB 1:5000
Antibody	Anti-alpha Tubulin (Mouse monoclonal)	Abcam	RRID: AB_2241126	WB 1:5000

Antibody	Anti-beta Actin (Mouse monoclonal)	Abcam	RRID: AB_449644	WB 1:5000
Software, algorithm	Image Studio Lite	LICOR		https://www.licor.com/bio/image-studio-lite/
Software, algorithm	FIJI	NIH	RRID: SCR_002285	https://fiji.sc/
Software, algorithm	GraphPad Prism	Other	RRID: SCR_002798	https://www.graphpad.com

Cell lines and cell culture

HEK 293T cells were cultured in DMEM with 10% FBS(VWR), NEAA

(Gibco, Cat No: 11140050) and 1mM Sodium Pyruvate (Gibco, Cat No:

11360070). For exosome production, we seeded cells at 10~20%

confluency in 150 mm tissue culture dishes (Fisher Scientific, Cat No: 12-

565-100) containing 30ml of exosome-free medium. Exosomes were

collected from 80% confluent cells (~48h).

Extracellular vesicle purification

Conditioned medium was harvested from 80-90% confluent HEK 293T

cultured cells. All procedures were performed at 4 ℃. Cells and large debris

were removed by centrifugation in a Sorvall R6+ centrifuge at 1,000xg for

15 min followed by 10,000xg for 15 min using a FIBERlite F14-6x500y rotor.

The supernatant fraction was then centrifuged onto a 60% sucrose cushion

which contained 10mM HEPES (pH 7.4) and 0.85% w/v NaCl at ~100,000

x g (28,000 RPM) for 1.5h in a SW32Ti rotor. The interface over the

sucrose cushion was collected and pooled for an additional centrifugation

onto a 2ml 60% sucrose cushion at ~120,000 x g (31,500 RPM) for 15h

using an SW41Ti rotor. The first collected interface was measured by refractometry and adjusted a sucrose concentration not exceeding 21%. For bulk purification, the EVs collected from the interface over the sucrose cushion after the first SW41Ti centrifugation were mixed with 60% sucrose to a final volume of 10ml (the concentration of sucrose ~50%). One ml of 40% and 1ml of 10% sucrose were sequentially overlaid and the samples were centrifuged at ~150,000 x g (36,500 rpm) for 15h in an SW41Ti rotor. The EVs were located at the 10%/40% interface and collected for RNA extraction or immunoblot.

Isolation of Mitochondria and Mitoplast

Mitochondria were isolated according to a well-established published protocol (Wang *et al.*, 2020). HEK293T Cells were harvested at 80% confluency and were homogenized in 6 vol of HB buffer (225 mM mannitol, 25 mM sucrose, 0.5% BSA, 0.5 mM EGTA, 30 mM Tris–HCl, pH 7.4, and protease inhibitors) in a prechilled Dounce homogenizer (Kontes), centrifuged and the postnuclear supernatant was collected. Crude mitochondria were centrifuged at 6,300 x g for 8 min, washed once with MRB buffer (250 mM mannitol, 0.5 mM EGTA, and 5 mM HEPES, pH 7.4), resuspended in 1ml MRB buffer, laid over a 30% Percoll solution (9ml) and centrifuged at 95,000g for 45min. The buoyant, purified fraction of mitochondria was collected for further analysis. For mitoplast purification, crude mitochondria were resuspended into 10 vol MRB buffer with 0.2 mg/ml digitonin and incubated on ice for 15 mins. Digitonin-treated crude mitochondria were laid over a 30% Percoll solution (9ml) and centrifuged at 95,000g for 45 min. A buoyant, purified fraction of mitoplasts was collected for further analysis.

YBAP1 Immunoprecipitation from mitochondria

After the Percoll gradient purification, the enriched mitochondria were diluted 2x into MRB buffer and centrifuged at 12,000g for 10 min. The mitochondrial pellet was lysed in 0.5ml RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 1% DDM, 1mM PMSF) containing protease inhibitors (1mM 4-aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine chloromethyl ketone and 1 µg/ml pepstatin) and RNase inhibitors. The mitochondrial lysate was centrifuged at 12,000g for 10 min. The supernatant fraction was incubated with 10ul washed protein A Dynabeads (ThermoFisher Scientific, Catalog number: 10001D) and 0.5ug mouse monoclonal IgG antibody and rotated at 4 ℃ for 1h. The supernatant was collected after a magnetic rack was used to remove protein A beads and incubated with 40ul washed protein A Dynabeads and 4ug YBAP1 antibody or mouse IgG antibody and rotated at 4 ℃ overnight. The beads were collected using a magnetic rack, washed 3x with 1ml of RIPA buffer, and collected for immunoblot and RNA extraction.

Mitochondria-Immunoprecipitation

Mito-IP was performed as previously described with slight modifications (Chen et al., 2016). The mito-IP cell-line was grown to ~90% confluency in 15cm dishes. All the subsequent steps of mito-IP were performed using ice-cold buffers either in a cold-room or on ice. The cells ($2x10^7$) were washed twice with 10ml of PBS. Cells were then harvested in 10ml of mito-

IP buffer (10mM KH2PO4, 137mM KCl) containing protease inhibitors (1mM 4-aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine chloromethyl ketone and 1 µg/ml pepstatin) and TCEP 0.5mM. The final mito IP buffer also contained 6ml of OptiPrep^{TM} (Sigma$^®$) per 100ml. Cells were collected at 700xg for 5 min and resuspended in 1ml of mito-IP buffer per 15cm plate. Cells were then lysed using 5-10 passes through a 22G needle and a post-nuclear supernatant (PNS) fraction was obtained after centrifuging the lysate at 1500xg for 10 min to remove unbroken cells and nuclei. Whenever necessary, a fraction of PNS was saved for immunoblot analysis. The resulting PNS was incubated with 100 µl of anti-HA magnetic beads (Sigma®) pre-equilibrated in the mito-IP buffer in 1.5ml microcentrifuge tubes and then gently rotated on a mixer for 15min. The beads were collected using a magnetic rack and washed 3x for 5min with 1ml of mito-IP buffer. To assess their quality, we assayed the immunoprecipitated mitochondria for the following protein markers by immunoblotting using the rabbit primary antibodies- anti-HA (1:1000), anti-COX IV (1:1000), anti-TOM20 (1:1000), anti-Citrate Synthase (1:1000), anti-RAB5 (1:1000), anti-LAMP1 (1:2000), anti-GAPDH (1:5000), and anti-GRP78 (Abcam$^®$) (1:3000). All of the above antibodies were sourced from Cell Signaling Technology$^®$, unless stated otherwise. As a negative control, non-transduced HEK293T cells were used in these experiments to assess the non-specific capture of the marker proteins.

Mitochondrial Fractionation

One mito-IP was performed per sample as described above. To ensure an even distribution of mitochondria across the samples, we pooled washed beads from all the IPs and equally distributed aliquots for subsequent treatments. Mitochondria were lysed in a 50µl final volume using either 1% vol/vol Triton X-100 (final concentration) or by three sequential rounds of freeze/thaw using liquid-nitrogen, as indicated. Urea was added to a final concentration of 3M. After a 10 min incubation on ice, samples were centrifuged at 15000xg for 15 min and supernatant and pellet fractions were collected as indicated. The total fractionated mitochondria were analyzed by immunoblotting for various mitochondrial markers. To analyze the specific RNA content of total or fractionated mitochondria, we extracted RNA using Trizol^{TM} (Invitrogen®) as per manufacturer's recommendations followed by q-PCR.

In vitro packaging of miR223 and miR223mut

Preparation of membranes and cytosol

The membrane and cytosol fractions were prepared from HEK293T cells as previously described with slight modifications (Shurtleff *et al.*, 2016; Temoche-Diaz *et al.*, 2020). All steps were carried out in either the cold-room or on ice using ice-cold buffers and pre-chilled equipment. Briefly, HEK293T cells (80% confluency) were washed twice with PBS and then harvested in the homogenization buffer (HB) (250 mM sorbitol, 20mM HEPES-KOH pH 7.4) containing protease inhibitor cocktail (1mM 4-aminobenzamidine dihydrochloride, 1 µg/ml antipain dihydrochloride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml chymostatin, 1 mM phenylmethylsulphonyl fluoride, 50 µM N-tosyl-L-phenylalanine chloromethyl ketone and 1 µg/ml pepstatin). The cell pellet was obtained by centrifuging the cells at 500xg for 5 min. After discarding the supernatant, cells were weighed and resuspended in two volumes of HB followed by lysis with 5-10 passages through a 22G needle. The lysate was centrifuged at 1500xg for 10 min to remove unbroken cells and nuclei to obtain a PNS. The resulting PNS was centrifuged at 20,000xg for 30 min to obtain a membrane fraction. The supernatant from above was centrifuged at 150,000xg for 30 min using a TLA-55 rotor (Beckman Coulter $^®$) and the resulting supernatant was used as the cytosol fraction (~6mg protein/ml). The membrane fraction from the first 20,000xg sedimentation was

resuspended in 1 ml of HB and centrifuged again at 20,000xg for 30 min.
The pellet fraction was resuspended in one volume of HB and rested on an
ice block for a minimum of 10 min until the insoluble components and
debris settled at the bottom of the tube. The finely resuspended material
was then transferred to a new microcentrifuge tube (to avoid the settled
debris) and was used as the membrane fraction.

Preparation of radiolabeled miR223 and miR223mut substrates

HPLC purified miR223 and miR223mut oligos were obtained from IDT®. A
stock solution of these oligos (1µl of a 10µM) was 5'-end-labeled using
T4PNK (NEB®) and 5µl of ATP, [γ-32P]- 6000Ci/mmol 10mCi/ml EasyTide
(PerkinElmer® BLU502Z250UC) as per manufacturer's recommendations
in a 50µl reaction volume. T4PNK was heat-inactivated at 70°C for 15 min.
Unincorporated radionucleotides were removed by passing through
PerformaTM spin columns (EdgeBio®). The flow-through (radiolabeled
substrate) was collected and stored at -20°C until further use.

In vitro miR223 packaging reaction

Wherever indicated, 10µl of cytosol (~5 mg/ml), 17µl of membranes, 2µl of
radiolabeled substrate, 9µl of 5x incorporation buffer (400 mM KCl, 100 mM
CaCl$_2$, 60 mM HEPES-NaOH, pH 7.4, 6 mM, MgOAc), 4.5µl of 10x ATP
regeneration system (400 mM creatine phosphate, 2 mg/ml creatine
phosphokinase, 10 mM ATP, 20 mM HEPES pH 7.2, 250 mM sorbitol, 150
mM KOAc, 5 mM MgOAc), 1µl of ATP (100mM, Promega®), 0.5µl of GTP
(100mM, Promega®), 1µl of Ribolock™ (40U/µL, Invitrogen®) were mixed to
setup a 45µl *in vitro* packaging reaction. In samples without the cytosol or
membranes, the final reaction volumes were adjusted to 45µl using HB.
The reactions were incubated at either 30°C or on ice, as indicated, for 15
min. Following the incubation, the indicated samples were subjected to
RNAse ONE™ (Promega®) using 10U of the enzyme in the presence of
urea (300mM final concentration) in a total reaction volume of 60µl.
Wherever indicated, TritonX-100 was added to a final concentration of 1%.
The RNAse treatments were carried out for 20 min at 30°C followed by
RNA extraction using DirectZol™ (Zymo Research®) kits as per
manufacturer's protocol. The RNA was precipitated overnight at -20°C by
the addition of 3 vol of ethanol, 1/10th volume of 3M sodium acetate (pH5.2)

and 30μg Glycoblue™ reagent (Invitrogen®). Precipitated RNA was
sedimented at 16,000xg for 30 min followed by washing with ice-cold 70%
ethanol. The RNA pellet was resuspended in 2X RNA loading dye (NEB®)
and heated for 5 min at 70°C. The RNA was separated using a 15%
denaturing polyacrylamide gel, followed by gel drying using a vacuum gel
dryer (Model 583, Biorad®). The bands were visualized by
phosphorimaging using a Kodak® storage phosphor screen and the Pharos
FX™ Plus Molecular Imager (Biorad®).

Immunoblots

Cell lysates and other samples were prepared by adding 2% SDS and

heated at 95 °C for 10mins. Protein was quantified using a BCA Protein

Assay Kit (Thermo Fisher Scientific) and appropriate amounts of samples

were mixed with 5x SDS loading buffer. Samples were heated at 95°C for

10min and separated on 4–20% acrylamide Tris-glycine gradient gels (Life

Technologies). Proteins were transferred to PVDF membranes (EMD

Millipore, Darmstadt, Germany), the membrane was blocked with 5% fat-

free milk powder in TBST and incubated for 1 h at room temperature or

overnight at 4°C with primary antibodies. Blots were then washed in 3

washes of TBST for 10 min each. Membranes were incubated with anti-

rabbit or anti-mouse secondary antibodies (GE Healthcare Life Sciences,

Pittsburgh, PA) for 1h at room temperature and rinsed in 3 washes of TBST

for 10 min each. Blots were developed with ECL-2 reagent (Thermo Fisher

Scientific). Primary antibodies used in this study were as follows: anti-

Tim23 (BD, 611222), Calnexin (Abcam, ab22595), Actin (Abcam, ab8224),

Tubulin (Abcam, ab7291), YBAP1 (Santa Cruz Biotechnology, sc-271200).

Immunofluorescence

Cells were cultured on 12mm round coverslips (corning) and were fixed with 4% EM-grade paraformaldehyde (Electron Microscopy Science, Hatfield, PA) in PBS pH7.4 for 10 min at room temperature. Cells were then washed 3x with PBS for 10min each, treated with permeabilizing buffer (10% FBS in PBS) containing 0.1% saponin for 20min and treated in blocking buffer for 30min. Subsequently, cells were incubated with primary antibodies in permeabilizing buffer for 1h at room temperature, washed 3x with PBS for 10 min each and incubated with secondary antibodies in permeabilizing buffer for 1h at room temperature and finally washed 3x with PBS for 10 min each. Cells were mounted in slides with Prolong Gold with DAPI (Thermo Fisher Scientific, P36931). Primary antibody used in the immunofluorescence studies were as follows: anti-YBX1 (Abcam, ab12148), YBAP1 (Santa Cruz Biotechnology, sc-271200). Images were acquired with Zeiss LSM900 confocal microscope and analyzed with the Fiji software (http://fiji.sc/Fiji).

Quantitative real-time PCR

Cellular and EV RNAs were extracted using a mirVana miRNA isolation kit (Thermo Fisher Scientific, AM1560) or Direct-zol RNA Miniprep kits (Zymo Research). Taqman miRNA assays for miRNA detection were purchased from Life Technologies. Assay numbers were: has-miR-223-3p, 002295; has-mir-190–5 p, 000489; U6 snRNA, 001973. Total RNAs were quantified using RNA bioanalyzer (Agilent). Taqman qPCR master mix with no Amperase UNG was obtained from Life Technologies for reverse transcription. For mRNA, RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, K1621) was used for reverse transcription. COX1 qPCR primers: Forward-5'-TCTCAGGCTACACCCTAGACCA-3', Reverse-5'-

590 ATCGGGGTAGTCCGAGTAACGT-3'. GAPDH qPCR primers: Forward-5'-
591 CTGACTTCAACAGCGACACC-3', Reverse-5'-
592 TAGCCAAATTCGTTGTCATACC-3'. Quantitative real-time PCR was
593 performed using an QuantStudio™ 5 Real-Time PCR System (Applied
594 Biosystems™)

Protein Purification

Twin Strep tag hybrid YBX1 was expressed and the protein was isolated
48h after PEI-mediated transfection of 293T cells. Cells were resuspended
in PBS and collected by centrifugation for 5 min at 600g. Pellet fractions
were resuspended in 35 ml lysis buffer (50mM Tris-HCl (PH=8),150mM
NaCl,1mM EDTA, 2mM DTT, 1mM PMSF and 1 x protease inhibitor
cocktail). After sonication of the cell suspension the crude lysate was
centrifuged for 60 min at 20,000 rpm at 4 °C. The resulting supernatant
fraction was incubated with 2 ml Strep-Tactin® Sepharose® resin (IBA, 2-
1201-010) for 1 h. Strep-Tactin® Sepharose® resin samples were
transferred to columns (18ml) and protein-bound beads were washed with
60ml wash buffer (50mM Tris-HCl (PH=8), 500mM NaCl, 1mM EDTA, 2mM
DTT) until no protein was eluted as monitored by the Bio-Rad protein assay
(Bio-Rad, Catalog #5000006). Proteins were eluted with 10 ml elution
buffer (50mM Tris-HCl (PH=8),150mM NaCl, 10mM desthiobiotin, 1mM
EDTA, 2mM DTT) and concentrated using an Amicon Ultra Centrifugal
Filter Unit (50 kDa, 4 ml) (Fisher Scientific, EMD Millipore). Proteins were
further purified by gel filtration chromatography (Superdex-200, GE
Healthcare) with columns equilibrated in storage buffer (50 mM Tris-HCl
7.4, 500 mM KCl, 5 % glycerol, 1 mM DTT). Peak fractions corresponding
to the appropriate fusion protein were pooled, concentrated, and distributed

in 10 µl aliquots in PCR tubes, flash-frozen in liquid nitrogen and stored at - 80 °C. Protein concentration was determined by known concentrations of BSA assessed by Coomassie Blue staining.

Tagged (6xHis) and maltose-binding protein hybrid genes were expressed. In baculovirus-infected SF9 insect cells (Lemaitre et al., 2019). Insect cell cultures (1 l, 1×10^6 cells/ml) were harvested 48 h after viral infection and collected by centrifugation for 20 min at 2000 rpm. The pellet fractions were resuspended in 35 ml lysis buffer (50 mM Tris-HCl 7.4, 0.5 M KCl, 5 % glycerol, 10mM imidazole, 0.5 µl/ml Benzonase nuclease (Sigma, 70746–3), 1 mM DTT, 1 mM PMSF and 1 x protease inhibitor cocktail). Cells were lysed by sonication and the crude lysate was centrifuged for 60 min at 20, 000 rpm at 4 °C. After centrifugation, the supernatant fraction was incubated with 2 ml Ni-NTA His-Pur resin (Thermo Fisher, PI88222) for 1 h. Ni-NTA resin samples were transferred to columns (18ml) and protein-bound beads were washed with 60ml lysis buffer until no protein was eluted as monitored by the Bio-Rad protein assay (Bio-Rad, Catalog #5000006). Proteins were eluted with 10 ml elution buffer (50 mM Tris-HCl 7.4, 0.5 M KCl, 5 % glycerol, 500mM imidazole). The eluted sample was incubated with 2 ml amylose resin (New England Biolabs, E8021L) for 1 h at 4°C. Amylose resin samples were transferred to columns and protein-bound beads were washed with 60ml lysis buffer until no protein was eluted as monitored by the Bio-Rad protein assay. Proteins were eluted with 10 ml elution buffer (50 mM Tris-HCl 7.4, 500 mM KCl, 5 % glycerol, 50 mM maltose). Proteins were concentrated using an Amicon Ultra Centrifugal Filter Unit (50 kDa, 4 ml) (Fisher Scientific, EMD Millipore). Proteins were further purified by gel filtration chromatography (Superdex-200, GE

Healthcare) with columns equilibrated in storage buffer (50 mM Tris-HCl 7.4, 500 mM KCl, 5 % glycerol, 1 mM DTT). Peak fractions corresponding to the appropriate fusion protein were pooled, concentrated, and distributed in 10 μl aliquots in PCR tubes, flash-frozen in liquid nitrogen and stored at –80 °C. Protein concentration was determined by known concentrations of BSA based on Coomassie Blue staining.

CRISPR/Cas9 genome editing

A pX330-based plasmid expressing Venus fluorescent protein (Shurtleff *et al.*, 2016) was used to clone the gRNAs targeting YBAP1. A CRISPR guide RNA targeting the first exon of the YBAP1 open reading frame was designed following the CRISPR design website (http://crispor.tefor.net/crispor.py): CGCTGCGTGCCCCGTGTGCT. Oligonucleotides encoding gRNAs were annealed and cloned into pX330-Venus as described (Cong et al., 2013). HEK293T cells were transfected by Lipofectamine 2000 for 48h at low passage number, trypsinized and sorted for single, Venus positive cells in 96 well plates by a BD Influx cell sorter. YBAP1 knockout candidates were confirmed by immunoblot. HEK 293T YBX1 knockout cells were generously provided by Dr. Xiaoman Liu (Liu *et al.*, 2021).

Electrophoretic mobility shift assay

Fluorescently labeled RNAs (5'-IRD800CWN) were ordered from Integrated DNA Technologies (IDT, Coralville, IA) for detecting free and protein-bound RNA. EMSA was performed as described (Rio, et al., 2014) with some modification. Briefly, 1 nM of IRD800CWN-labeled RNA was incubated with increasing amounts of purified proteins, ranging from 500 pM - 1 μM.

Buffer E was used in this incubation (25 mM Tris pH8.0, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EGTA, 0.05% Nonidet P-40, 1 mM DTT, 5% glycerol, 50 ug/ml heparin). Reactions were incubated at 30 ℃ for 30min then chilled on ice for 10 min. Samples were mixed with 6x loading buffer (60 mM KCl, 10 mM Tris pH 7,6, 50% glycerol, 0.03% (w/v) xylene cyanol). Mixtures (5ul) were loaded onto a 6% native polyacrylamide gel at 200V for 45mins in a cold room. The fluorescence signal was detected using an Odyssey CLx Imaging System (LI-COR Biosciences, Lincoln, NE). The software of the Odyssey CLx Imaging System was used to quantify fluorescence. To calculate Kds, we fitted used Hill equations with quantified data points.

Data availability

All data generated or analyzed in this study are included in the manuscript and supporting files. Source data files have been provided for Figure 1b, Figure 1c, Figure 1f, Figure 1g, Figure 1-figure supplement 1a-c, Figure 2b, Figure 2g, Figure 2-figure supplement 1a-f, Figure 3b, Figure 3d, Figure 3g, Figure 3 supplement 1b-c, Figure 4a, Figure 4b, Figure 4e, Figure 4f, Figure 4h, Figure 4i, Figure 4-figure supplement 1a-b, Figure 4-figure supplement 2a, Figure 5b.

Article and author information

Author details

Liang Ma

Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, United States

Contribution: Conceptualization, Investigation, Methodology, Writing - original draft, Writing - review and editing

Competing interests: No competing interests declared

ORCID icon 0000-0003-3227-5917

Jasleen Singh

Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, United States

Contribution: Contribution of mito-IP, mitochondrial fractionation, and in vitro packaging assay

Competing interests: No competing interests declared

Randy Schekman

Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, United States

Contribution: Conceptualization, Funding acquisition, Investigation, Supervision, Writing - review and editing

For correspondence: schekman@berkeley.edu

Competing interests: Reviewing editor, eLife

ORCID icon 0000-0001-8615-6409

Funding

Howard Hughes Medical Institute (Investigator) and Aligning Science Across Parkinson's Disease

Randy Schekman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Dr. Samantha Lewis for advice about localization to mitochondria and for sharing a plasmid; thanks Matthew J Shurtleff, David Melville, Shenjie Wu, Jordan Ngo, Congyan Zhang, Justin Williams, Morayma M Temoche-Diaz for suggestions and reading and editing the manuscript. We also thank staff at the UC Berkeley shared facilities, the Cell Culture Facility, the Flow Cytometry Facility and QB3-Berkeley (The California Institute for Quantitative Biosciences at UC Berkeley). LM and JS are supported as Research Associates of the HHMI. RS is an Investigator of the HHMI, a Senior fellow of the UC Berkeley Miller Institute of Science and Scientific Director of Aligning Science Across Parkinson's Disease.

References

Cha, D.J., Franklin, J.L., Dou, Y., Liu, Q., Higginbotham, J.N., Demory Beckler, M., Weaver, A.M., Vickers, K., Prasad, N., Levy, S., et al. (2015). KRAS-dependent sorting of miRNA to exosomes. Elife *4*, e07197. 10.7554/eLife.07197.

Chen, W.W., Freinkman, E., Wang, T., Birsoy, K., and Sabatini, D.M. (2016). Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell *166*, 1324-1337 e1311. 10.1016/j.cell.2016.07.040.

Chevillet, J.R., Kang, Q., Ruf, I.K., Briggs, H.A., Vojtech, L.N., Hughes, S.M., Cheng, H.H., Arroyo, J.D., Meredith, E.K., Gallichotte, E.N., et al. (2014).

Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A *111*, 14888-14893. 10.1073/pnas.1408301111.

Cocucci, E., Racchetti, G., and Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol *19*, 43-51. 10.1016/j.tcb.2008.11.003.

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science *339*, 819-823. 10.1126/science.1231143.

Correia-Melo, C., Ichim, G., Tait, S.W., and Passos, J.F. (2017). Depletion of mitochondria in mammalian cells through enforced mitophagy. Nat Protoc *12*, 183-194. 10.1038/nprot.2016.159.

Harding, C., Heuser, J., and Stahl, P. (1983). Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol *97*, 329-339. 10.1083/jcb.97.2.329.

Huang, L., Mollet, S., Souquere, S., Le Roy, F., Ernoult-Lange, M., Pierron, G., Dautry, F., and Weil, D. (2011). Mitochondria associate with P-bodies and modulate microRNA-mediated RNA interference. J Biol Chem *286*, 24219-24230. 10.1074/jbc.M111.240259.

Jeandard, D., Smirnova, A., Tarassov, I., Barrey, E., Smirnov, A., and Entelis, N. (2019). Import of Non-Coding RNAs into Human Mitochondria: A Critical Review and Emerging Approaches. Cells *8*. 10.3390/cells8030286.

Liu, X.M., Ma, L., and Schekman, R. (2021). Selective sorting of microRNAs into exosomes by phase-separated YBX1 condensates. Elife *10*. 10.7554/eLife.71982.

Lyons, S.M., Achorn, C., Kedersha, N.L., Anderson, P.J., and Ivanov, P. (2016). YB-1 regulates tiRNA-induced Stress Granule formation but not translational repression. Nucleic Acids Res *44*, 6949-6960. 10.1093/nar/gkw418.

Matsumoto, K., Tanaka, K.J., and Tsujimoto, M. (2005). An acidic protein, YBAP1, mediates the release of YB-1 from mRNA and relieves the translational repression activity of YB-1. Mol Cell Biol *25*, 1779-1792. 10.1128/MCB.25.5.1779-1792.2005.

Mittelbrunn, M., Gutierrez-Vazquez, C., Villarroya-Beltri, C., Gonzalez, S., Sanchez-Cabo, F., Gonzalez, M.A., Bernad, A., and Sanchez-Madrid, F. (2011). Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun *2*, 282. 10.1038/ncomms1285.

Mukherjee, K., Ghoshal, B., Ghosh, S., Chakrabarty, Y., Shwetha, S., Das, S., and Bhattacharyya, S.N. (2016). Reversible HuR-microRNA binding controls extracellular export of miR-122 and augments stress response. EMBO Rep *17*, 1184-1203. 10.15252/embr.201541930.

Muta, T., Kang, D., Kitajima, S., Fujiwara, T., and Hamasaki, N. (1997). p32 protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix

and is functionally important in maintaining oxidative phosphorylation. J Biol

Chem *272*, 24363-24370. 10.1074/jbc.272.39.24363.

Pegtel, D.M., Cosmopoulos, K., Thorley-Lawson, D.A., van Eijndhoven, M.A.,

Hopmans, E.S., Lindenberg, J.L., de Gruijl, T.D., Wurdinger, T., and Middeldorp,

J.M. (2010). Functional delivery of viral miRNAs via exosomes. Proc Natl Acad

Sci U S A *107*, 6328-6333. 10.1073/pnas.0914843107.

Santangelo, L., Giurato, G., Cicchini, C., Montaldo, C., Mancone, C., Tarallo, R.,

Battistelli, C., Alonzi, T., Weisz, A., and Tripodi, M. (2016). The RNA-Binding

Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery

Controlling MicroRNA Sorting. Cell Rep *17*, 799-808.

10.1016/j.celrep.2016.09.031.

Shurtleff, M.J., Temoche-Diaz, M.M., Karfilis, K.V., Ri, S., and Schekman, R.

(2016). Y-box protein 1 is required to sort microRNAs into exosomes in cells and

in a cell-free reaction. Elife *5*. 10.7554/eLife.19276.

Shurtleff, M.J., Yao, J., Qin, Y., Nottingham, R.M., Temoche-Diaz, M.M.,

Schekman, R., and Lambowitz, A.M. (2017). Broad role for YBX1 in defining the

small noncoding RNA composition of exosomes. Proc Natl Acad Sci U S A *114*,

E8987-E8995. 10.1073/pnas.1712108114.

Temoche-Diaz, M.M., Shurtleff, M.J., Nottingham, R.M., Yao, J., Fadadu, R.P.,

Lambowitz, A.M., and Schekman, R. (2019). Distinct mechanisms of microRNA

sorting into cancer cell-derived extracellular vesicle subtypes. Elife *8*.

10.7554/eLife.47544.

Temoche-Diaz, M.M., Shurtleff, M.J., and Schekman, R. (2020). Buoyant Density

Fractionation of Small Extracellular Vesicle Sub-populations Derived from

Mammalian Cells. Bio Protoc *10*, e3706. 10.21769/BioProtoc.3706.

Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar,

A., Zhang, L., Merchant, M.L., et al. (2017). MVP-mediated exosomal sorting of

miR-193a promotes colon cancer progression. Nat Commun *8*, 14448.

10.1038/ncomms14448.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lotvall, J.O.

(2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel

mechanism of genetic exchange between cells. Nat Cell Biol *9*, 654-659.

10.1038/ncb1596.

Villarroya-Beltri, C., Gutierrez-Vazquez, C., Sanchez-Cabo, F., Perez-Hernandez,

D., Vazquez, J., Martin-Cofreces, N., Martinez-Herrera, D.J., Pascual-Montano, A.,

Mittelbrunn, M., and Sanchez-Madrid, F. (2013). Sumoylated hnRNPA2B1

controls the sorting of miRNAs into exosomes through binding to specific motifs.

Nat Commun *4*, 2980. 10.1038/ncomms3980.

Wang, W.X., Prajapati, P., Nelson, P.T., and Springer, J.E. (2020). The

Mitochondria-Associated ER Membranes Are Novel Subcellular Locations

Enriched for Inflammatory-Responsive MicroRNAs. Mol Neurobiol *57*, 2996-
3013. 10.1007/s12035-020-01937-y.
Wozniak, A.L., Adams, A., King, K.E., Dunn, W., Christenson, L.K., Hung, W.T.,
and Weinman, S.A. (2020). The RNA binding protein FMR1 controls selective
exosomal miRNA cargo loading during inflammation. J Cell Biol *219*.
10.1083/jcb.201912074.

Figure legends

Figure 1. YBX1 directly and specifically binds miR223.

(a.) RT-qPCR analysis of relative abundance of miR223 detected in exosomes compared to cellular level at 293T WT cells or YBX1 knockout cells. Data are plotted from 3 independent experiments, each independent experiment with triplicate qPCR reactions; error bars represent standard deviations. (b-c.) EMSA assays using 1nM 5' fluorescently labeled miR223 or miR190 and purified YBX1. Purified YBX1 was titrated from 500pM to 1μM. In gel fluorescence was detected. Quantification of (d.) shows the calculated Kd. (e.) Schematic diagrams of the different domains of YBX1. (f.) EMSA assay using 1nM 5' fluorescently labeled miR223 and purified YBX1 truncations. [YBX1(1-51) or YBX1(52-129) or YBX1(130-324).] (g.) EMSA assay using 1nM 5' fluorescently labeled miR223 and purified YBX1 truncations [YBX1(1-129) or YBX1(52-324)] or YBX1(F85A) mutant.

Figure 1-figure supplement 1. Purified YBX1 full length protein and different truncations and mutation.

(a-c.) YBX1 full length protein or different truncations were overexpressed and purified from insect cells.

Figure 2. miR223 sequence motif UCAGU binds YBX1

(a.) RNA oligonucleotides corresponding to miR223, miR190 and versions with mutated sorting motif (miR223mut) or mutation to introduce the sorting motif (miR190sort). (b.) EMSA assays using 1nM 5' fluorescently labeled miR223 WT or miR223mut or miR190 WT or miR190sort and purified YBX1. Purified YBX1 was titrated from 500pM to 1µM. In gel fluorescence was detected. (c.) Binding affinity curves as calculated by EMSA data from (b.) (d.) Schematic shows exosome purification with buoyant density flotation in a sucrose step gradient from 293T cells overexpressing miR223 WT or mutant or miR190 WT or miR190sort. (e.) RT-qPCR analysis of relative abundance of miR223 or miR223mut detected in exosomes compared to cellular level in 293T cells overexpressing miR223 WT or miR223mut. Data are plotted from 3 independent experiments and error bars represent standard derivations. (f.) RT-qPCR analysis of relative abundance of miR190 or miR190sort detected in exosomes compared to cellular level in 293T cells overexpressing miR190 WT or miR190sort. Data are plotted from 3 independent experiments and error bars represent standard derivations. (g.) *In vitro* packaging assay using ^{32}P 5'end-labeled miR223 and miR223mut. Cell-free packaging of miR223 and miR223mut measured as protected radioactive signal from ^{32}P labeled miR223 and miR223mut. Reactions with or without membrane, cytosol, and 1% Triton X-100, and incubated at 4 or 30 °C are indicated. For the samples containing only cytosol plus membrane at 4 °C, only one-third of the samples were loaded. Each sample was supplemented with 300mM urea to reduce the background signal. (h.) Data quantification showed protected fraction of miR223 and miR223mut as calculated from *in vitro* packaging data shown in (g.)

Figure 2-figure supplement 1. Screening of exosomal sorting motif of miR223.

EMSA competition assay to screen the exosomal sorting motif of miR223. (a.-f.) EMSA competition assay using 1nM 5' fluorescently labeled miR223, 32nM purified YBX1 protein and unlabeled miR223 or miR223mutants. Unlabeled miR223 or miR223mutants were titrated from 1nM to 1μM.

Figure 3. Mitochondria contribute to miR223 enrichment into exosomes.

(a.) Tom22-mCherry expressing HeLa cells were transfected with Atto-647 labeled miR223, cultured for 4h and observed by confocal microscopy. Scale bar, 5 μm. The data shown on the right is the fluorescence intensity of the different channels indicated by a solid white line. (b.) Immunoblot analysis of protein markers for different subcellular fractions isolated from 293T cells. (c.) RT-qPCR analysis of miR223 fold changes of different subcellular fractions isolated from 293T cells relative to cell lysate. (d.) Immunoblot analysis of protein markers for mitoplasts purified from 293T cells. (e.) RT-analysis of COX1 mRNA, miR223 and U6 snRNA fold changes for mitoplasts purified from 293T cells relative to cell lysate. (f.) RT-qPCR analysis of mitochondrial mRNA COX1 in GFP-Parkin expressing U2OS cells treated with or without CCCP. Data are plotted from 3 independent experiments and error bars represent standard derivations. (g.) Immunoblot analysis of mitochondrial marker Tim23 in GFP-Parkin expressing U2OS cells treated with or without CCCP. (h.) RT-qPCR analysis showed an increase in miR223 in GFP-Parkin expressing cells treated with CCCP. Data are plotted from 3 independent experiments and error bars represent standard derivations. (i.) Schematic of exosome purification from mitochondrial-depleted GFP-Parkin expressing U2OS

cells. (j.) RT-qPCR analysis showing the enrichment of exosomal miR223 was decreased after GFP-Parkin expressing cells were treated with CCCP. Data are plotted from 3 independent experiments and error bars represent standard derivations.

Figure 3-figure supplement 1. miR223, but not miR190, enriched in mitochondria.

(a.) RT-qPCR analysis of miR190 fold changes in subcellular fractions isolated from 293T cells relative to cell lysate. Data are plotted from 3 independent experiments and error bars represent standard derivations. (b.) Mitochondria immunoprecipitation. Mitochondria purified from 293T WT or 3xHA-EGFP-OMP25 overexpressing cell line using anti-HA magnetic beads. Immunoblot detection of inner membrane marker COX IV, outer membrane marker TOM20 and mitochondrial matrix protein citrate synthase (CS) but not of the early endosome marker RAB5, lysosome marker LAMP1, cytosol marker GAPDH and ER marker GRP78. (c.) Purified mitochondria from (b.) were treated with 1% Triton X-100 or freeze/thaw using liquid-nitrogen and the supernatant and pellet fractions were collected after centrifugation. Immunoblot analysis of the mitochondrial protein distribution of outer membrane protein TOM20, inner membrane protein COX IV and matrix protein citrate synthase. (d.) and (e.) RT-qPCR analysis of the distribution of COX1 mRNA and miR223 from (c.)

Figure 4. YBAP1 directly and specifically binds miR223.

(a.) Strep II-YBX1 was overexpressed into 293T cells. Coomassie blue detection of unknown band copurified with YBX1 from 293T cells. (b.) Immunoblot identifies unknown band was YBAP1. (c.) Tom22-mCherry

expressing U2OS was transfected with YBAP1-GFP, cultured for 12h and observed by confocal microscopy. Scale bar, 10 μm. (d.) Quantification of the fluorescence intensity of the different channels indicated by the solid white line of (c.). (e.) YBAP1 resides in mitochondria. Proteinase K protection assay for YBAP1 using purified mitochondria from 293T cells. Samples were treated with or without proteinase K (10 ug/ml) and or Triton X-100 (0.5%). Immunoblots for Tim23, Tom20 and YBAP1 are shown. (f.) Mitochondria were purified for immunoprecipitation with YBAP1 antibody. Immunoblot detection of YBAP1 and Tom20. (g.) RT-qPCR analysis of miR223 fold changes of YBAP1 IP samples. Data are plotted from 3 independent experiments and error bars represent standard derivations. (h-i.) EMSA assays using 1nM 5' fluorescently labeled miR223 or miR190. Purified YBAP1 was titrated from 500pM to 1μM. In gel fluorescence was detected. Quantification of (j.) shown the calculated Kd.

Figure 4-figure supplement 1. YBX1 and YBAP1 copurify as a complex from transfected SF9 cells.

(a.) YBAP1 purified from insect cells which overexpressed His-MBP-YBAP1. (b.) YBX1 and YBAP1 were copurified from insect cells which overexpressed His-MBP-YBX1 and no tagged YBAP1.

Figure 4-figure supplement 2. YBAP1 does not share the same miR223-binding motif as YBX1.

(a.) EMSA assays using 1nM 5' fluorescently labeled miR223 WT or miR223mut or miR190 WT or miR190sort and purified YBAP1. Purified YBAP1 was titrated from 500pM to 1μM. In gel fluorescence was detected. (b.) Binding affinity curves as calculated by EMSA data from (a.)

Figure 5. YBAP1 sequesters miR223 which is released and secreted in YBAP1 KO cells

(a.) Schematic shows exosome and mitochondria purification from 293T WT cells and YBAP1 knock out cells for RT-qPCR analysis. (b.) Analysis of 293T WT and CRISPR/Cas9 genome-edited cells by immunoblot for YBAP1 (top) and actin (bottom). (c.) RT-qPCR analysis of miR223 enrichment in mitochondria purified from 293T WT cells and YBAP1 KO cells relative to cell lysate. Data are plotted from 3 independent experiments and error bars represent standard derivations. (d.) RT-qPCR analysis of miR223 enrichment in exosomes isolated from 293T WT cells and YBAP1 KO cells relative to cell lysate. Data are plotted from 3 independent experiments and error bars represent standard derivations.

Figure 6. YBX1 puncta relocalize from mitochondria to endosomes.

(a.) YBX1 puncta on the mitochondria. U2OS cells were stained with anti-YBX1 and anti-YBAP1 antibodies and observed by confocal microscopy. The right panel shows enlarged regions of interest from the left panel. Scale bar, 5 μm. (b.) YBX1 puncta relocalize from mitochondria to endosomes. U2OS cells overexpressed YFP-YBX1, Rab5(Q79L)-mCherry and mito-BFP. Time-lapse images were acquired with a Zeiss LSM900 confocal microscope. Scale bar, 2 μm.

Figure 7. Diagram representing a model of miR223 sorting from mitochondria into exosomes.

Stages in the transfer of miR223 from mitochondria. Cytosolic miR223 is enriched in mitochondria where it may be sequestered by a weak

interaction with YBAP1. Cytoplasmic YBX1 interacts more tightly with

miR223 which may drive the removal of miR223 from mitochondria. YBX1

in RNA granules may accumulate miR223 removed from mitochondria.

YBX1 puncta may give rise to small particles carrying miR223 for uptake

into endosomes and secretion in exosomes.

Figure 1 – source data. Uncropped gel images corresponding to Figure 1.

Figure 1 – figure supplement 1 – source data. Uncropped gel images
corresponding to Figure 1 supplement 1.

Figure 2 – source data. Uncropped gel images corresponding to Figure 2.

Figure 2 – figure supplement 1 – source data. Uncropped gel images
corresponding to Figure 2 supplement 1.

Figure 3 – source data. Uncropped immunoblot images corresponding to
Figure 3.

Figure 3 – figure supplement 1 – source data. Uncropped immunoblot
images corresponding to Figure 3 supplement 1.

Figure 4 – source data. Uncropped immunoblot and gel images
corresponding to Figure 4.

Figure 4 – figure supplement 1 – source data. Uncropped gel images
corresponding to Figure 4 supplement 1.

Figure 4 – figure supplement 2 – source data. Uncropped gel images
corresponding to Figure 4 supplement 2.

Figure 5 – source data. Uncropped immunoblot images corresponding to
Figure 5.

Figure 1. YBX1 directly and specifically binds miR223

Figure 1-figure supplement 1. Purification of YBX1 full length protein and different truncations and mutation

a.

b.

c.

His-MBP-YBX1

YBX1(1-51)
YBX1(52-129)
YBX1(130-324)

YBX1(1-129)
YBX1(52-324)
YBX1(F85A)

Figure 2. miR223 sequence motif UCAGU binds YBX1

a.

miR223-3p UG**UCAGU**UUGUCAAAUACCCCA
miR223mut UG**AGACA**UUGUCAAAUACCCCA

miR190-5p UG**AUAUG**UUUGAUAUAUUAGGU
miR190sort UG**UCAGU**UUUGAUAUAUUAGGU

c.

b.

miR223   miR223mut   miR190   miR190sort

d. Transfect plasmid which express miRNAs or mutants

medium → 1,500 g / 10,000 g → Supernatant → 100,000 g / 120,000 g → Sucrose cushion (10% 40% 60% EV) → 150,000 g → Exosomes

e. p=0.0013

f. p=0.0194

g.

	miR223						**miR223mut**					
Temp (℃)	30	30	30	30	4	4	30	30	30	30	4	4
RNase I	+	+	+	+	+	—	+	+	+	+	+	—
Membranes	—	+	+	+	+	+	—	+	+	+	+	+
Cytosol	+	—	+	+	+	+	+	—	+	+	+	+
Triton(1%)	—	—	—	+	—	—	—	—	—	+	—	—

h.

Figure 2-figure supplement 1. Screening exosomal sorting motif of miR223

Figure 3. Mitochondria contribute to miR223 enrichment into exosomes

Figure 3-figure supplement 1. miR223, but not miR190, enriched in mitochondria.

Figure 4. YBAP1 binds miR223 in the mitochondria and in vitro

[miRNA] = 1nM
Kd of miR223 = 173.2nM

Figure 4-figure supplement 1. YBX1 and YBAP1 copurify as a complex from transfected SF9 cells.

a.

His-MBP-YBAP1

b.

His-MBP-YBX1

YBAP1

Copurify from Insect cell

Figure 4-figure supplement 2. YBAP1 does not share the same motif as YBX1 that binds to miR223

a.

Figure 5 . YBAP1 sequesters miR223 which is released and secreted in YBAP1 KO cells

a.

Cell

Mitochondria

medium

RNA Extraction and RT-qPCR

WT or YBAP1-KO

Exosome

b.

293T WT

YBAP1-KO

α-YBAP1

α-Actin

c.

p=0.0458

miR223 enrichment
(Mitochondria VS cell)

WT

YBAP1-KO

d.

p=0.0079

miR223 enrichment
(EV vs cell)

WT

YBAP1-KO

Figure 6. YBX1 puncta relocalize from mitochondria to endosomes

a.

YBX1
YBAP1

5µm

b. YFP-YBX1 Rab5(Q79L)-mC mito-BFP

0s

3m48s

6m39s

2µm

9m30s

10m27s

28m28s

Figure 7. Diagram representing a model of miR223 sorting from mitochondria into exosomes